Autosomal dominant polycystic kidney
Drug research and approvals for autosomal dominant polycystic kidney: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 34 studies of autosomal dominant polycystic kidney are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 1 approved and 18 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 34
- Trials authorized in Canada: 6
- FDA orphan approvals: 1
- EU medicines: 1
- Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseNCT07868926 · Phase 1 · Vertex Pharmaceuticals Incorporated · starts Oct 16, 2026
- Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesNCT07792408 · Phase 1 · Vertex Pharmaceuticals Incorporated · starts Sep 1, 2026
- A Phase 1 Study of Single and Multiple Ascending Doses of GV-100NCT07788014 · Phase 1 · Gilva Therapeutics Inc. · starts Jun 23, 2026
- Managing Depressive Symptoms in ADPKDNCT07745920 · Not applicable · Mayo Clinic · starts Jun 12, 2026
- RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT…NCT07535385 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Aug 17, 2020
- Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseNCT07454174 · Not applicable · Richard Fatica · starts Feb 25, 2026
- Bempedoic Acid Therapy for Polycystic Kidney DiseaseNCT07282821 · Phase 2 · Kenneth Hallows · starts Sep 1, 2026
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney DiseaseNCT07280585 · Phase 3 · University of Cologne · starts Dec 16, 2025
- Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney DiseaseNCT07260071 · Not reported · King's College London · starts Aug 15, 2025
Approved 1
- TolvaptanVasopressin V2 receptor antagonist
Phase 3 12
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- LixivaptanVasopressin V2 receptor antagonist
- LanreotideSomatostatin receptor 5 agonist
- PravastatinHMG-CoA reductase inhibitor
- OctreotideSomatostatin receptor agonist
- EverolimusFK506-binding protein 1A inhibitor
- SpironolactoneMineralocorticoid receptor antagonist
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- Bardoxolone methylPeroxisome proliferator-activated receptor gamma antagonist
- SomatostatinSomatostatin receptor agonist
- Triptolide
Phase 2 8
- TesevatinibEphrin type-B receptor 4 inhibitor
- VenglustatCeramide glucosyltransferase inhibitor
- BosutinibTyrosine-protein kinase ABL inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- TamibaroteneRetinoic acid receptor beta agonist
- ImidaprilAngiotensin-converting enzyme inhibitor
- CilnidipineVoltage-gated L-type calcium channel blocker
- GLPG-2737
How its trials ended
151 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 39 whose ending is known, 51% met their primary endpoint, 10% missed it and 38% stopped early.
- Completed, result not reported5436%
- Ongoing4228%
- Met its primary endpoint2013%
- Status unknown1611%
- Stopped: sponsor or business decision64%
- Missed its primary endpoint43%
- Stopped: lack of efficacy43%
- Stopped: other or unclear32%
- Stopped: safety11%
- Stopped: enrollment or feasibility11%
| Mar 27, 2025 | A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-CLS-628 in adult subjects with autosomal…ABBV-CLS-628 | Calico Life Sciences LLC | Ongoing |
| Mar 19, 2025 | A randomised, double blind, placebo-controlled, single ascending dose, phase 1a/1b multi-centre study in healthy participants and participants with autosomal…GSK4771261 | GSK | Ongoing |
| Nov 2, 2021 | A phase 3 study of the efficacy and safety of lixivaptan in participants with autosomal dominant polycystic kidney disease consisting of a 1-year double-blind,…Lixivaptan | Palladio Biosciences | Ongoing |
| Apr 9, 2021 | Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (gz/SAR402671) in…Venglustat (SAR402671) | Sanofi-Aventis Canada Inc | Pending |
| Sep 6, 2018 | Multicenter, randomized, double-blind, placebo-controlled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of…Venglustat (GZ/SAR402671) | Sanofi | Ongoing |
| Jun 27, 2016 | A pilot study of cystic volume reduction by foam sclerotherapy in autosomal dominant polycystic kidney diseaseSodium tetradecyl sulfate | University Health Network | Ongoing |
| Apr 23, 2018 | JynarqueJYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease… | Otsuka Pharmaceutical Company, Ltd. | Approved |
| Aug 19, 2026 | Eukaryotic ribosome-selective glycosideTreatment of autosomal dominant polycystic kidney disease | Eloxx Pharmaceuticals | Designated |
| Jul 8, 2026 | Human IgG1kappa monoclonal antibody that specifically binds…Treatment of autosomal dominant polycystic kidney disease | AstraZeneca Pharmaceuticals LP | Designated |
| Mar 26, 2026 | TamibaroteneTreatment of autosomal dominant polycystic kidney disease | Rege Nephro Co., Ltd. | Designated |
| Nov 1, 2025 | Fully human IgG1 monoclonal antibody that binds to human…Treatment of autosomal dominant polycystic kidney disease | Calico Life Sciences LLC | Designated |
| Sep 8, 2025 | OctreotideTreatment of autosomal dominant polycystic kidney disease | Camurus AB | Designated |
| Sep 5, 2025 | SalsalateTreatment of autosomal dominant polycystic kidney disease | J & D Pharmaceuticals LLC | Designated |
| Aug 29, 2025 | Anti-PAPPA mAbTreatment of autosomal dominant polycystic kidney disease (ADPKD) | GlaxoSmithKline Research & Development Limited | Designated |
| Feb 12, 2024 | (S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy-1…Treatment of autosomal dominant polycystic kidney disease (ADPKD) | Shanghai Alebund Pharmaceuticals Ltd. | Designated |
| Apr 20, 2023 | OxypurinolTreatment of autosomal dominant polycystic kidney disease | XORTX Therapeutics Inc. | Designated |
| Nov 22, 2022 | MebendazoleTreatment of Autosomal Dominant Polycystic Kidney Disease | Healx Technology Limited | Designated |
| Sep 14, 2022 | Potassium…Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | SCYNEXIS, Inc. | Designated |
| Jun 16, 2022 | A chemically modified full phosphorothioate-backbone…Autosomal dominant polycystic kidney disease (ADPKD) | Novartis Pharmaceuticals Corporation | Designated |
| May 26, 2021 | TesevatinibTreatment of autosomal dominant polycystic kidney disease | Kadmon Corporation | Designated |
| Jun 3, 2019 | Bardoxolone methylTreatment of autosomal dominant polycystic kidney disease | Reata Pharmaceuticals, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 27, 2015 | JinarcTolvaptan | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA